The biggest stories of the day delivered to your inbox.

We create communities of learning that amplify Pulitzer Center journalism through education and outreach programs, connecting teachers, students, artists, influencers, and decision makers with stories ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock-full of ...

The company said the growth in revenue compared to 2024 is expected to be largely driven by new Lilly medicines such as Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new ...

Lilly's involvement will add a new dimension to Purdue's focus on pharma manufacturing research, which was consolidated around the William D Young Institute for Advanced Manufacturing of ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

Theweek is part of Future US Inc, an international media group and leading digital publisher. Visit our corporate site. © Future US, Inc. Full 7th Floor, 130 West ...

Eli Lilly's focus on expanding its drug portfolio, including Zepbound and Mounjaro, alongside new launches like imlunestrant for metastatic breast cancer, is expected to fuel revenue growth in the ...

(RTTNews) - Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The company's earnings came in at $4.409 billion ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that ...

Composer Raven Chacon is a Pulitzer Prize winner and MacArthur Fellow ... into this volcanic rock on the westside of Albuquerque, New Mexico, where I'm from. These drawings were made by my ...